PMID- 34435138
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 16
IP  - 1
DP  - 2021
TI  - Phosphoglycerate mutase 2 is elevated in serum of patients with heart failure and 
      correlates with the disease severity and patient's prognosis.
PG  - 1134-1142
LID - 10.1515/med-2021-0324 [doi]
AB  - BACKGROUND: Heart failure (HF) is a serious and advanced stage of various cardiac 
      diseases with high mortality and rehospitalization rates. Phosphoglycerate mutase 
      2 (PGAM2) overexpression was identified in the serum of patients with HF. 
      MATERIAL/METHODS: One hundred and fifty-three cases of HF were included in the 
      present work. According to New York Heart Association (NYHA) classification, 22 
      were grade II, 84 were grade III, and 47 were grade IV. Serum PGAM2, NT-proBNP, 
      B-type natriuretic peptide (BNP), troponin T (TNT), and Cys-C of HF patients were 
      detected using ELISA assay. Left ventricular ejection fraction, left ventricular 
      end-diastolic inner diameter, and left atrium (LA) inner diameter of the included 
      cases were also detected by the cardiac color Doppler. RESULTS: The number of 
      patients with atrial fibrillation was significantly higher in NYHA IV group than 
      in groups II and III with statistical difference (p < 0.05). The serum PGAM2, 
      NT-proBNP, and Cys-C were significantly higher in NYHA IV group than in NYHA II 
      and NYHA III groups (p (all) < 0.05). NT-proBNP had the highest prediction 
      efficacy of HF severity and PGAM2 was also a potential biomarker for HF severity 
      evaluation with relatively high sensitivity, specificity, and area under the ROC. 
      The overall survival among NYHA II, III, and IV groups were statistically 
      different (p = 0.04) with the median survival time of 25 months for NYHA III and 
      IV groups. CONCLUSION: PGAM2 is a new promising biomarker for evaluation of the 
      severity of HF. Combination detection using multiple serum factors such as PGAM2, 
      NT-proBNP, BNP, TNT, and Cys-C can improve the HF severity differential diagnosis 
      performance.
CI  - (c) 2021 Min Li et al., published by De Gruyter.
FAU - Li, Min
AU  - Li M
AD  - Department of Emergency, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan 250100, China.
FAU - Gao, Xiaoyuan
AU  - Gao X
AD  - Department of Cardiovascular Medicine, Jinan Central Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan 250100, China.
FAU - Wang, Huiyun
AU  - Wang H
AD  - Research Center of Translational Medicine, Jinan Central Hospital, Cheeloo 
      College of Medicine, Shandong University, Jinan 250100, China.
FAU - Zhang, Mingli
AU  - Zhang M
AD  - Department of Emergency, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan 250100, China.
FAU - Li, Xiaoying
AU  - Li X
AD  - Department of Emergency, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan 250100, China.
FAU - Wang, Shuya
AU  - Wang S
AD  - Department of Cardiovascular Medicine, Jinan Central Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan 250100, China.
FAU - Wang, Shaoqin
AU  - Wang S
AD  - Department of Emergency, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan 250100, China.
FAU - Cao, Chongfeng
AU  - Cao C
AD  - Department of Intensive Care Unit, Jinan Central Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan 250100, China.
FAU - Li, Ying
AU  - Li Y
AD  - Research Center of Translational Medicine, Jinan Central Hospital, Cheeloo 
      College of Medicine, Shandong University, No. 105 Jiefang Road, Lixia District, 
      Shandong Province, Jinan 250100, China.
FAU - Su, Guohai
AU  - Su G
AD  - Department of Cardiovascular Medicine, Jinan Central Hospital, Cheeloo College of 
      Medicine, Shandong University, No. 105 Jiefang Road, Lixia District, Shandong 
      Province, Jinan 250100, China.
LA  - eng
PT  - Journal Article
DEP - 20210811
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC8359905
OTO - NOTNLM
OT  - HF
OT  - NYHA
OT  - PGAM2
OT  - biomarker
OT  - cardiac function grading
COIS- Conflict of interest: Authors state no conflict of interest.
EDAT- 2021/08/27 06:00
MHDA- 2021/08/27 06:01
PMCR- 2021/08/11
CRDT- 2021/08/26 06:18
PHST- 2021/02/20 00:00 [received]
PHST- 2021/06/23 00:00 [revised]
PHST- 2021/07/02 00:00 [accepted]
PHST- 2021/08/26 06:18 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/08/27 06:01 [medline]
PHST- 2021/08/11 00:00 [pmc-release]
AID - med-2021-0324 [pii]
AID - 10.1515/med-2021-0324 [doi]
PST - epublish
SO  - Open Med (Wars). 2021 Aug 11;16(1):1134-1142. doi: 10.1515/med-2021-0324. 
      eCollection 2021.